Treatment and prevention of virus infections in immunosuppressed patients.
D000212:Acyclovir / Q000009:adverse effects / Q000627:therapeutic use*; D002644:Chickenpox / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D004311:Double-Blind Method; D006561:Herpes Simplex / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D006562:Herpes Zoster / Q000188:drug therapy / Q000628:therapy; D006566:Herpesviridae Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D004854:Herpesvirus 4, Human; D006801:Humans; D007108:Immune Tolerance; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D014740:Vidarabine / Q000009:adverse effects / Q000627:therapeutic use*
D007370:Interferon Type I; D014740:Vidarabine; D000212:Acyclovir